Fibrates: no ACCORD on their use in the treatment of dyslipidaemia
- 1 August 2010
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 21 (4) , 352-358
Abstract
New data have emerged over the last few years about the role of fibrates in treatment of microvascular and macrovascular disease. Endpoint studies have been conducted with fibrates in coronary heart disease since 1971 and results have been contradictory. Fibrates have shown benefits in patients with low HDL-cholesterol and low LDL-cholesterol. Fibrates remain topical, given their actions on the lipid triad present in the metabolic syndrome and in diabetes. In the Fenofibrate Intervention in Endpoint Lowering in Diabetes study of mixed primary and secondary prevention cohorts, fenofibrate therapy resulted in an 11% reduction in coronary or cardiovascular events in monotherapy. Despite frequent use, there was little endpoint data on fibrate–statin combination therapy until recently. The Action to Control Cardiovascular Risk in Diabetes trial of fenofibrate added to baseline simvastatin therapy in diabetes showed a nonsignificant 8% reduction in cardiovascular events. The benefits were concentrated in men, and women did slightly worse with fibrate therapy. In post-hoc analysis, slight beneficial effects of fenofibrate were seen in patients with moderate hypertriglyceridaemia (>2.3 mmol/l) and low HDL-cholesterol (<0.88 mmol/l). The safety profile of fibrate–simvastatin combination was good. Fenofibrate and bezafibrate are reasonable second-line therapies for dyslipidaemia and in diabetes. They are safe in combination therapy with statins but add little endpoint benefit except possibly in patients with a significant degree of atherogenic dyslipidaemia (high triglycerides and low HDL-cholesterol). The benefits of fibrates on microvascular disease remain to be fully explored.Keywords
This publication has 64 references indexed in Scilit:
- Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysisBMJ, 2009
- European guidelines on cardiovascular disease prevention in clinical practice: Executive summaryAtherosclerosis, 2007
- HDL-c is a powerful lipid predictor of cardiovascular diseasesInternational Journal Of Clinical Practice, 2007
- Triglycerides and the Risk of Coronary Heart DiseaseCirculation, 2007
- High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patientsCurrent Medical Research and Opinion, 2005
- Efficacy and safety of high-density lipoprotein cholesterol-increasing compoundsJACC, 2005
- Pioglitazone Reduces Atherogenic Index of Plasma in Patients with Type 2 DiabetesClinical Chemistry, 2004
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype.Current Atherosclerosis Reports, 2000
- Familial lipoprotein disorders and premature coronary artery diseaseAtherosclerosis, 1994